Research and Markets : Central Nervous System - Schizophrenia Drug Pipeline Report
Posted on: Wednesday, 11 July 2007, 09:04 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c62187) has announced the addition of Central Nervous System - Schizophrenia Drug Pipeline Report to their offering.
"Central Nervous System - Schizophrenia Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of schizophrenia drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Content Outline:
RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Schizophrenia Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects
--Legend
--Top 20 companies in late stage Schizophrenia Projects
--Top 20 companies in early stage Schizophrenia Projects
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--Approved Pipeline View
For more information visit http://www.researchandmarkets.com/reports/c62187
Source: Life Science Analytics
Source: Business Wire
Related Articles
- Pima County, Arizona Contracts with Motorola to Provide Project 25 Phase 2 TDMA
- ALS Therapy Development Institute, the World's Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
- Heartland Oil and Gas Continues Production Enhancement and Well and Pipeline Expansion Projects in Texas and Kansas
- BP Launches Open Season on Proposed Pipeline Reversal Project to Bring Light Canadian Crude to Cushing
- ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial
- Energy Transfer Partners, L.P. Continues Timely Completion of 42-Inch Pipeline Construction Project
- Energy Transfer Partners, L.P. Announces Completion of First Phase of 42-Inch Pipeline Expansion Project
- Start-Up Gets $36 Million: TetraLogic, of Malvern, is Developing Drugs That Help the Body Kill a Variety of Cancer Cells
- Green Hills Software and I-Logix Redefine ``Integrated Development Environment'' With First Single Source Solution Addressing All Phases of Embedded Systems Development
- Behavioral Therapies for Drug Abuse
 |
 |
User Comments (0)
RSS Feeds